Effects of intermittent hemodialysis on plasmatic levels of endocan
Crit Care
.
2021 Nov 29;25(1):412.
doi: 10.1186/s13054-021-03829-6.
Authors
Maxence Hureau
1
2
3
4
,
Julien Poissy
4
5
,
Daniel Mathieu
1
2
3
4
,
Sylvain Dubucquoi
6
,
Alexandre Gaudet
7
8
9
10
Affiliations
1
Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, 59000, Lille, France.
2
CNRS, UMR 9017, 59000, Lille, France.
3
INSERM, U1019, 59000, Lille, France.
4
CHU Lille, Pôle de Médecine Intensive - Réanimation, Hôpital Roger Salengro, 59000, Lille, France.
5
Univ. Lille, Inserm U1285, CHU Lille, CNRS, UMR 8576, UGSF, Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.
6
Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, 59000, Lille, France.
7
Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, 59000, Lille, France. alexandre.gaudet@chru-lille.fr.
8
CNRS, UMR 9017, 59000, Lille, France. alexandre.gaudet@chru-lille.fr.
9
INSERM, U1019, 59000, Lille, France. alexandre.gaudet@chru-lille.fr.
10
CHU Lille, Pôle de Médecine Intensive - Réanimation, Hôpital Roger Salengro, 59000, Lille, France. alexandre.gaudet@chru-lille.fr.
PMID:
34844658
PMCID:
PMC8628438
DOI:
10.1186/s13054-021-03829-6
No abstract available
MeSH terms
Humans
Neoplasm Proteins* / blood
Proteoglycans* / blood
Renal Dialysis*
Treatment Outcome
Substances
ESM1 protein, human
Neoplasm Proteins
Proteoglycans